logo
Borderlands Mexico: Source Logistics eyes rising US demand for Hispanic brands

Borderlands Mexico: Source Logistics eyes rising US demand for Hispanic brands

Yahoo20-04-2025

Borderlands Mexico is a weekly rundown of developments in the world of United States-Mexico cross-border trucking and trade. This week: Source Logistics eyes rising US demand for Hispanic brands; South Korean automotive supplier opens $160M facility in Mexico; Otay Mesa border crossing secures $150M federal grant; and CBP snags $14M in meth from tractor-trailer.
With Hispanics making up 20% of the U.S. population and growing annually, officials at Source Logistics see big opportunities to bring food and beverage brands from south of the border into the U.S. market.
'With these fast-growing companies, you need a logistics partner that is willing and able to grow with you, to expand with you, to make the beds with you,' Raul Villarreal, CEO of Source Logistics, told FreightWaves in an interview.
Source Logistics, with its headquarters near Houston, is a provider of transportation, warehousing, distribution and fulfillment services.
The company was founded in 1999 by Villarreal and Marcelo Sada, former CEO and now president of corporate development.
Since the beginning, Source Logistics has focused on helping Hispanic food and beverage brands expand into the U.S. market. That effort has only become more relevant over the years.
The U.S. Hispanic/Latino population grew to just over 65 million in 2023, an increase 1.8% from the prior year, according to the latest figures from the U.S. Census Bureau.
U.S. Hispanic/Latino purchasing power is currently measured at $3.78 trillion, according to a recent report from think tank The Latino Donor Collaborative.
'We are truly focused on the import business. We help companies abroad; we understand what they go through when they're trying to penetrate the market,' Villarreal said. 'When we sit down and we talk about potential solutions, we think one of the most important things is that we see each individual customer as a unique customer with unique challenges. It allows us to really find or identify potential solutions for customers that are bringing products from abroad.'
One brand that Source Logistics has helped to grow in the U.S. is Electrolit, a popular Mexican hydration beverage.
'The Electrolit brand is one of the fastest-growing beverage brands with double-digit annual growth rates,' Daniel Dibos, supply chain and logistics director at Electrolit USA, said in a news release that also credited Source Logistics' 10-year partnership with Electrolit.
The next phase of Source Logistics' growth plans includes targeting markets in Atlanta, Florida and the Mid-Atlantic U.S., and adding 20% capacity to the company's existing footprint.
The strategy is supported by recent investments from New York-based financial services firm Palladium Equity Partners, which acquired Source Logistics in November 2023. The firm has invested $1.5 billion in the U.S. Hispanic market since Palladium was founded in 1997.
Since the beginning of the year, Source Logistics has opened a 271,000-square-feet warehouse in Dallas, along with a 425,000-square-foot warehouse in Laredo, Texas.
Source Logistics also recently acquired the warehousing business of LaGrou Distribution, adding 2 million square-feet of logistics space across eight new warehouses in the Chicago area.
With the recent acquisition and new warehouses, Source Logistics has a total network of 5.6 million square feet of logistics space in 24 locations across the U.S., including Los Angeles, Portland, Oregon; Houston; and New Jersey.
Villarreal said the company can now offer distribution services to reach over 75% of the U.S. population within the same day.
'Part of our strategy is to eventually reach 95% of the U.S. population within same-day transportation,' Villarreal said. 'Before we acquired LaGrou, we were covering 71% of the Hispanic population in the U.S. and 52% of the U.S. population. With the acquisition, we increase our reach to 80% of the Hispanic population and 75% U.S. population.'
Seojin Mobility recently completed the first phase of construction for an auto parts plant in the Mexican city of General Escobedo.
The factory will manufacture components for electric vehicles and create 300 direct jobs. The initial investment in the facility was $160 million, according to a news release.
A second phase of construction at the factory is scheduled to be completed in 2028 and includes an additional investment of $140 million.
General Escobedo is about 14 miles north of Monterrey and 155 miles south of Laredo.
Seojin Mobility, headquartered in Siheung, South Korea, is the primary supplier for Hyundai and Kia and also works with General Motors, Ferrari, Renault and Volvo.
The Otay Mesa East-Otay II border crossing project recently received a $150 million grant from the U.S. Department of Transportation.
Otay Mesa is on the border with Tijuana, Mexico, just south of San Diego.
The grant will be used to complete construction of the new port of entry, as well as the project's technology package, according to a news release.
Otay Mesa East-Otay II will be 3 miles east of the original Otay Mesa port of entry. It will include 10 lanes – five for passenger vehicles and five for cargo transport. The project's total cost has been estimated at more than $1 billion.
Construction on the U.S. side is scheduled to begin in the fall with the plan of opening in late 2027. Construction on the Mexican side of the border is almost complete.
U.S. Customs and Border Protection officers recently seized more than 300 packages of alleged methamphetamine from a truck entering the U.S. from Mexico.
On April 11 at the Pharr-Reynosa International Bridge in Pharr, Texas, CBP officers discovered the alleged meth concealed in a shipment of fresh bell peppers and cucumbers, according to a news release.
The alleged narcotics have a street value of $14.62 million.
CBP officers seized the narcotics and vehicle and turned the case over to Homeland Security Investigations. CBP did not say if the truck driver was arrested or released.
The post Borderlands Mexico: Source Logistics eyes rising US demand for Hispanic brands appeared first on FreightWaves.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease

Yahoo

time19 minutes ago

  • Yahoo

AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease

Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) -- AriBio Co., Ltd. ("AriBio"), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. "This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide," said Jai Jun Choung, CEO of AriBio. "Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions." "We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries," said Isabel Afonso, CEO of Arcera. "This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs." The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease CONTACT: Tanya Xi, MD, PhD, MBA, Senior Director, Business Development & Medical Affairs, AriBio (US) AriBio Co., Ltd. tanyaxi@ Rafael Ferrer, SVP Corporate Development. Arcera rferrer@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Green Bay's Mayor Genrich joins Latino Professionals for civic engagement event
Green Bay's Mayor Genrich joins Latino Professionals for civic engagement event

Yahoo

time2 hours ago

  • Yahoo

Green Bay's Mayor Genrich joins Latino Professionals for civic engagement event

GREEN BAY, Wis. (WFRV) – Mayor Eric Genrich joined State Representative Amaad Rivera-Wagner and members of the Latino Professionals Association of Northeast Wisconsin (LPA) at City Hall for a vibrant discussion on civic engagement, representation, and the role of Latino professionals in local government. Posted to Facebook, the event, hosted in partnership with the Greater Green Bay Chamber, brought together nearly 100 community members to explore ways to empower Latino voices in politics and public service. With a growing Latino population in the region, the event focused on encouraging voter participation, exploring pathways to leadership, and strengthening the ties between community organizations and local government. Founded in 2021, the LPA has quickly become a hub for Latino professionals seeking career growth, advocacy, and networking in Northeast Wisconsin. Its mission—to advance Latino influence across industries—aligns closely with Green Bay's ongoing goals of fostering inclusivity and civic participation. Fans react to Jaire Alexander's release from the Packers after six seasons Mayor Genrich emphasized the vital role that diverse voices play in shaping the future of Green Bay. 'When we open doors for all members of our community to engage in civic life, we create a stronger, more representative city,' Genrich said during the event. 'Organizations like the LPA are essential partners in that effort.' Attendees heard from LPA leadership, learned about strategies for civic engagement, and took part in a networking session designed to build stronger connections between city leadership and Latino professionals. The evening was coordinated by Maria Padilla, Diverse Small Business Manager at the Greater Green Bay Chamber. Padilla highlighted the importance of events like this in building bridges across communities and promoting long-term participation in local governance. 'This conversation was about more than just politics—it was about creating a sense of belonging and ownership in the future of our city,' Padilla noted. The event marks another step in Green Bay's commitment to inclusive governance and ensuring that all voices have a seat at the table. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease

Business Upturn

time2 hours ago

  • Business Upturn

AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease

Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) — AriBio Co., Ltd. ('AriBio'), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. Advertisement AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. 'This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide,' said Jai Jun Choung, CEO of AriBio. 'Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions.' 'We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries,' said Isabel Afonso, CEO of Arcera. 'This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs.' The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store